AstraZeneca PLC Investor Conference Call: Farxiga's DAPA-CKD Trial at ESC 2020 Transcript
Good afternoon, everybody. Thank you so much for joining us for this very exciting discussion today on a very, very important set of data that we have just presented at the ESC.
So if we move to the Slide 3, this shows you the agenda for today. I will give you a short introduction, and then you will hear Professor Hiddo Heerspink present the data, and then we'll move to a Q&A.
So if we move to Slide 4, just want to say that the presenters for today will be Hiddo, of course; David Wheeler from University College London; Ruud Dobber, our EVP for our BioPharmaceuticals Business Unit; Mene Pangalos, the EVP for BioPharma R&D; and Elisabeth Björk, who is with the SVP for CVRM. They are available for the Q&A, and we may also call on other team members who are with us today in case we have additional questions.
We move to Slide 5. This slide actually shows you the, I would think, the incredible journey that Farxiga has been on from the early days when basically everybody saw this molecule as a simple diabetes drug
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
